<zh class="lnuok"></zh>

森林舞会官网

Be the most trusted biotech company

2025-04-24

Henlius to Present Latest Research Results at ASCO 2025
2025-04-17

Henlius' Innovative Anti-HER2 mAb HLX22 in Combination with T-Dxd Advances to a Phase 2 Clinical Trial for the Treatment of HER2-low, HR-positive BC with First Patient Dosed
2025-04-17

Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights
2025-04-16

Henlius to Present Latest Results of Serplulimab in Gastric Cancer at IGCC 2025
2025-04-15

Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report
2025-04-09

First Subject Dosed for a Phase 1b/2 Clinical Trial of Henlius’ PD-L1-Targeting ADC HLX43 in Combination with Novel Anti-PD-1 mAb Serplulimab
2025-04-09

The Henlius 2025 Global R&D Day is about to kick off
2025-04-09

Primary Endpoint Met in Phase 3 Clinical Study of Henlius Bevacizumab for Treatment of Ophthalmic Diseases
2025-04-01

Henlius to Present Three Preclinical Studies at AACR 2025